Dupilumab Treatment Approved for COPD with Raised Eosinophils
NICE has recommended dupilumab as a new treatment option for certain people with chronic obstructive pulmonary disease who have raised eosinophil levels.
Introduction
NICE has published guidance recommending dupilumab COPD treatment for adults with chronic obstructive pulmonary disease who have raised blood eosinophils and continue to experience exacerbations despite standard therapy.
Who Is Eligible for Dupilumab COPD Treatment
Dupilumab is recommended for adults whose COPD is not adequately controlled with triple inhaled therapy. This includes those who continue to have exacerbations and have raised eosinophil levels, indicating a type of inflammation that may respond to biologic treatment.
How Dupilumab COPD Treatment Works
Dupilumab is a monoclonal antibody that targets specific pathways involved in inflammation. By reducing this inflammation, the treatment can lower the frequency of exacerbations in people with COPD.
Clinical Benefits
Evidence reviewed by NICE shows that dupilumab reduces the number of exacerbations in eligible patients. This provides an additional treatment option for people with COPD who remain symptomatic despite existing therapies.
Conclusion
NICE recommends dupilumab COPD treatment as an option for adults with severe COPD and raised eosinophils who continue to experience exacerbations. This offers a new targeted therapy to help improve disease control.
Recent Resources
